康方生物临床试验药“失控”背后:授权收入“断奶”,创新“缩水”、销售“内卷”,合规防线如何失守

华夏时报
Yesterday

当救命药变成“问题药”,一家明星药企的合规防线,究竟是如何在利益与监管的博弈中轰然倒塌的?  近日,康方生物因“临床试验抗癌药流入市场”一事被推上舆论风口浪尖。一位重庆宫颈癌患者李某美的用药经历,撕开了这家创新药企光鲜外表下的巨大隐患。这场风波不仅关乎患者的生命健康,更暴露出企业在管理、业绩与行业生态中的多重危机。  多方责任待解,合规管理存疑  在医药行业创新驱动发展的进程中,康方生物曾凭借技术...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10